Brexit Reflections For UK IVDs: Harmonized Regulation, Staff Issues Key
The UK in vitro diagnostics industry has been working on two initiatives that set out its views on how to secure a stable and competitive future for the national industry in the months following the country's vote to leave the EU.
You may also be interested in...
With the clock running down on Brexit, bemused UK medtechs are ready to seize any information that helps them chart a way forward on trading with the EU in the absence of solid directions from the government. Frustrated by the Brexit vacuum, local manufacturers are actively looking to build businesses beyond the EU and focusing on innovation adoption at home, as ABHI policy director Richard Phillips explains.
The EU In Vitro Diagnostics Regulation and Brexit loom large for UK IVD companies, but manufacturers serving the $1.6bn UK IVD market have many other competing concerns. It’s the most challenging period in more than 15 years, according to the British In Vitro Diagnostics Association Chief Executive Doris-Ann Williams.
A national federation of medtech associations is being proposed by parts of the UK industry, which often feels muscled out of the debate by pharma for big issues like handling the country's exit from the EU. The argument is that a less fragmented sector voice would have more influence on government decisions.